Vidiia is transforming assay development and on-site diagnostics with innovative AI technology. By 2029, we aim to accelerate 100 assays through our Assay Accelerator.Our platform leverages AI to turn academic research into impactful, cost-effective diagnostics, identifying and unlocking dormant or unknown assays.
We are committed to democratising diagnostic testing with low-cost, portable, AI-powered solutions that can be used anywhere, by anyone.Vidiia identify the need to bridge research and real-world application, enhancing efficiency and ensuring global accessibility, setting new industry standards in diagnostic innovation.
A game-changing team of researchers, technology and operational experts brought together in 2020 to pursue a new breed of low cost disease diagnostics deployable anywhere in the field, by anyone.
Collaborating with leading molecular biotech universities – our purpose is to accelerate diagnostic development, enabling small scale, smart, remote disease testing using Vidiia’s AI-powered technologies.
Our range of scalable testing technologies and products are simple to use, fast, accurate and secure.
CEO and Cofounder
Cofounder
Chief Digital Innovator
Head of Science
Project Manager and R&D expert
Business Development Director
Head of School of Biosciences and Medicine at the University of Surrey
Head of Business Development & Innovation at Brunel University London
Professor Wamadeva Balachandran
Accesible , Portable, AI-Driven Testing
Testing by anyone, anywhere, anytime